Histone deacetylase inhibitors for enhancing activity of antifungal agent: A patent evaluation of WO2014041424(A1)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 2, 2015, Pages 237-240

  Zhang, Lei ^a   Xu, Wenfang ^b  

^a QINGDAO UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Antifungal; Histone deacetylase; Inhibitor; Selectivity

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; HISTONE DEACETYLASE INHIBITOR;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOASSAY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATENT; CANDIDA; DRUG DESIGN; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; DRUG DESIGN; DRUG SYNERGISM; FLUCONAZOLE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; PATENTS AS TOPIC;

EID: 84922357701     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.981256     Document Type: Article

References (16)

1. De Ruijter AJM, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
2. Foglietti C, Filocamo G, Cundari E, et al. Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281(26):17968-76
3. Lee JH, Maskos K, Huber R. Structural and functional studies of the yeast class II Hda1 histone deacetylase complex. J Mol Biol 2009;391(4):744-57
4. Jin YH, Jeon EJ, Li QL, et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004;279(28):29409-17
5. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4(1):5
6. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007;26(37):5310-18.
7. Ververis K, Hiong A, Karagiannis TC, et al. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013;7:47-60
8. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42.
9. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32.
10. Ueki N, Lee S, Sampson NS, et al. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nature Commun 2013;4:2735
11. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13(9):673-91
12. Zhang L, Fang H, Xu W. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev 2010;30(4):585-602.
13. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. P Natl Acad Sci USA 1998;95(6):3003-7
14. Ueda H, Nakajima H, Hori Y, et al. Fr901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium-Violaceum No-968. 1. Taxonomy, Fermentation, Isolation, Physicochemical and Biological Properties, and Antitumor-Activity. J Antibiot 1994;47(3):301-10
15. Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002;46(11):3532-9.
16. Pfaller MA, Messer SA, Georgopapadakou N, et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009;47(12):3797-804.